Swiss HLG Basel Networking Event - speaker bios

Celine Bouquet

Celine Bouquet is the BD Head of Neuroscience, Ophthalmology and Rare Diseases, Basel at Roche. Celine oversees the partnering transactions in these therapeutic areas and works closely with Roche’s internal research and development organization to identify opportunities that shape the Roche portfolio. She brings knowledge and experience from having led deals herself in various therapeutic areas while in Roche Pharma Partnering as well as her prior role, where she was overseeing portfolio prioritization, strategy setting and external alliances in the R&D organization from early discovery to Ph2. Celine joined Roche in 2012 and was heading the “Institut Roche”, dedicated to developing collaborative projects with academic partners to accelerate the transfer of basic research discoveries into innovative therapies in France. Prior to joining Roche, Celine gained experience and network across biotech, academia and tech transfer.An Ecole Normale Superieure de Lyon fellow, Celine holds a PhD in neuroscience from University Paris 6 and did her postdoctoral training in neuro-ophthalmology at UCSF. 

Elisabeth Aloy

Elisabeth Aloy, PhD, is the Head of Strategy at Roche Diagnostics. She has a dual background as a neuroscientist and a business leader in strategy, accelerating portfolio development and maximizing commercial value. She also has nearly two decades of strategy consulting experience, serving as a strategy consulting partner at Monitor Deloitte and leading the CNS and Rare Disease EMEA consulting practice at IQVIA.

Roberto Villasenor

Roberto Villaseñor is a Principal Scientist in pRED, where he leads the Brain Delivery group within the Neuroscience discovery and translational area. Roberto obtained his PhD from the Max Planck Institute for Cell Biology and Genetics in Dresden, with a background in Cell Biology. In 2014, he joined Roche to work on the Brainshuttle™ platform where he pioneered the study of the cellular mechanisms for transport across the blood-brain barrier. He has since taken on roles of increasing responsibility in the areas of blood-brain barrier biology, ADME of biologics, human in vitro model systems, and Neuroscience drug discovery. Currently, he leads the cross-functional preclinical Brainshuttle platform in Neuroscience and champions the development of novel therapeutic agents to treat Alzheimer's disease.